1. Jonathan Pirkl, VP of Business Development
A Clinical Stage Drug Company Developing Polymolecular Therapeutics For The Oncology, Neurology And Orthopedic Markets
Jonathan Pirkl, VP of Business Development

2. COMBINATORIAL TARGETING
THE PROBLEM
OUR SOLUTION
Most diseases have multifactorial causes and hence are driven by multiple factors. This helps to explain marginal outcomes and the high rate of failure in new drug development..
Involves identification of novel combinatory targets based on preclinical and clinical efficacy data using our Polymolecular Botanical Drug platform
COMBINATORIAL TARGETING
At the core of our platform is the conviction that unlike many pharmaceuticals, botanical compounds are heterogeneous with multiple active components that are able to modulate multiple mechanisms through COMBINATORIAL TAGETING to combat disease progression.

3. Timeline
Patents filed in USA & internationally (composition of matter and use claims)
Technology developed at University of Florida
Preclinical phase completed
Clinical studies begin 2018
Incorporated in Delaware in November 2012
Exclusive, world-wide license to the technology acquired by Prana Therapeutics, Inc. in 2017
Over 600K raised: grant & research contract, founders

4. Epidiferphane™ 1 2 3 Proprietary blend of 3 botanical compounds
developed & owned by Prana Therapeutics 1 2 3
Catechin from green tea
Curcumin
[potent anti-inflammatory]
Sulforaphane
[nature’s most potent anti-oxidant regulator]
Supplement
Epidiferphane™
Marketing Opportunities
Drug

5. R & D PROGRAM DRUG DEVELOPMENT PROGRAM
2018
2019
2020
2021
2022
Phase I/II
Phase III
Preventing Chemotherapy Side-effects
Phase I/II
Phase III
Inflammatory Disease
Back Pain & Arthritis
Phase I
Phase II
Cancer
High Grade Glioma
Phase III
Pre-clinical Testing
Clinical Testing

6. Current Market Size Preventing Chemotherapy Side-effects
Annual Sales
Notes
# Patients per year
Preventing Chemotherapy Side-effects
650K
$12B
Largely an unmet need, with no therapies to prevent
Inflammatory Disease
Back Pain
Arthritis
91M
$17B
Plethora of treatments, many have significant side effects
46M
$15B
Cancer
High Grade Glioma
Our approach is meant as an adjunctive treatment used together with standard of care
23K
$0.4B

7. Product Development Workflow
DISCOVERY: Tissue Culture & Animal Models are used to Identify Poly molecular Therapeutics
First Products are Engineered for the Supplement Market
STAGE 01
Based on preclinical and limited clinical data
PMBS [PolyMolecular Botanical Supplement]
PMBS Undergo Rigorous FDA Clinical Trial Evaluation Intended for New Drug Approval [NDA]
STAGE 02
PMBD [Poly Molecular Botanical Drug]
FDA Approved PMBD will be Developed into Synthetic Drugs Based on Successful
STAGE 03
PMSD [PolyMolecular Synthetic Drug]

8. Attenuating the side effects of Chemotherapy
NO THERAPIES EXIST to prevent these side effects which are often treatment limited, diminish treatment efficacy & reduce quality of life.
Each year in the USA there are approximately:
Over 90% of chemotherapy pts. experience at least one of the following negative side-effects:
1.6M
New Cancer Diagnosis
Anemia
Low red blood cells
Chemotherapy Induced Peripheral Neuropathy
650K
New Chemotherapy Pits
Neutropenia
Low white blood cells
Memory Problems
Chemo fog or Chemo brain

9. Attenuating the side effects of Chemotherapy
Anemia
Neutropenia
Epidiferphane™ when given with chemotherapy prevents 4 major negative side effects of chemotherapy
Neuropathy
Neural stem cells

10. Inflammatory Disease
Back pain and arthritis
75% of responders saw improvement with an average improvement of 50%
75% of responders saw improvement with an average improvement of 45%
100% of responders saw improvement with an average improvement of 60%
How often were you in a bed or chair most or all of the day?
Did you have trouble doing vigorous exercise?
How often do you have severe pain from your arthritis?

11. Inflammatory Disease
Back pain and arthritis
75% of responders saw improvement with an average improvement of 50%
75% of responders saw improvement with an average improvement of 60%
75% of responders saw improvement with an average improvement of 50%
How often does morning stiffness last for more than 1 hour?
How often does the pain make it difficult to sleep?
How often have you felt tense or high strung?

12. NO EFFECTIVE THERAPIES EXIST to treat Stage IV gliomas or Glioblastoma
Cancer
High Grade Glioma
Epidiferphane™ when combined with a low carb [LC] diet has been demonstrated to:
Increase survival of human tumors in a rodent
Work synergistically with chemotherapy
Sensitize chemotherapy resistant tumors to standard of care drugs
NO EFFECTIVE THERAPIES EXIST to treat Stage IV gliomas or Glioblastoma
Each year in the USA there are approx. 80K new brain cancer diagnoses
The most common type, Glioblastoma, has a survival diagnosis of approximately 12 months.
Epidiferphane™ when combined with a low carb diet doubles mean life expectancy

13. OUR PARTNERS
CLINICAL TRIAL SITES

14. FOUNDERS MANAGEMENT BOARD OF DIRECTORS
Brent Reynolds, Ph.D.
Brent Reynolds, Ph.D.
Brent Reynolds, Ph.D.
Prof Neurosurgery, University of Florida
President
Founder & President Prana Therapeutics
Dennis Steindler, Ph.D.
Courtney Simmons, M.Ed.
Earnie Blackmon
SVP of Program Management
CEO United Cannabis
Director Neuroscience and Aging Lab,
Tufts University
John Walsh
Ben Griffith, B.Sc.
CFO United Cannabis
Loic Deleyrolle, Ph.D.
Project Manager
Res Asst Prof, University of Florida